Screening for Anti-Inflammation Quality Markers of Lianhua Qingwen Capsule Based on Network Pharmacology, UPLC, and Biological Activity
Influenza is a common respiratory infectious disease. In China, Lianhua Qingwen capsule (LHQWC), a drug with significant clinical efficacy and few side effects, is commonly used to treat influenza. However, the composition of LHQWC is complicated, and currently used quality control methods cannot en...
Saved in:
Main Authors: | Yongfeng Zhou (Author), Ming Niu (Author), Dingkun Zhang (Author), Zhenxing Liu (Author), Qinghua Wu (Author), Jiang Chen (Author), Haizhu Zhang (Author), Ping Zhang (Author), Jin Pei (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Establishment of an anti-inflammation-based bioassay for the quality control of the 13-component TCM formula (Lianhua Qingwen)
by: Shuaishuai Chen, et al.
Published: (2021) -
The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis
by: Caiyun Hu, et al.
Published: (2022) -
Predicting for anti-(mutant) SARS-CoV-2 and anti-inflammation compounds of Lianhua Qingwen Capsules in treating COVID-19
by: Liang Hong, et al.
Published: (2022) -
A meta-analysis for Lianhua Qingwen on the treatment of Coronavirus disease 2019 (COVID-19)
by: Jieqin Zhuang, et al.
Published: (2021) -
Qualitative analysis of chemical components in Lianhua Qingwen capsule by HPLC-Q Exactive-Orbitrap-MS coupled with GC-MS
by: Shuai Fu, et al.
Published: (2021)